Dr. Michael Breggar, VP of Life Sciences for Business & Decision, Addresses Governance in Cloud Computing at Stevens Institute of Technology
HOBOKEN, N.J., Nov. 8, 2011 /PRNewswire/ -- Dr. Michael Breggar addressed an audience of business executives and academics on the topic of governance in the deployment of cloud computing solutions at the Cloud Computing Consortium(C3) Conference at Stevens Institute of Technology. Dr. Breggar, a member of the C3 Governance Working Group, participated in a panel discussion and question-and-answer session that included Alex Birukoff of The IT Advisory, Nigel Blower of IT Evolution, Incorporated, Darnee A. Phipps of Microsoft, and Jeffrey Wu of Actionable Strategies.
Dr. Breggar emphasized the need for a detailed plan for governance in a cloud environment, stating that "while some view the cloud as 'plug and play,' I am convinced of the need for a structured approach." He also suggested that moving to the cloud should begin with an assessment of the risks, ROI and benefits on an application by application basis, adding "if you see your information as an asset, your approach to the cloud must be strategic and asset-structured as well."
The Cloud Computing Consortium (C3) was created to provide C level executives with a strong, impartial resource with the knowledge and practical experience necessary to effectively and efficiently transition to the world of cloud computing and navigate through all of the competing claims. It operates from within the Stevens Center for Information Research at Stevens Institute of Technology in New Jersey, USA.
Dr. Michael Breggar is the Vice President of Life Sciences for Business & Decision. With a career spanning nearly thirty years of life science and health care management consulting, Dr. Breggar's specialties include operational and performance improvement strategy, FDA regulatory strategy, complex computer system compliance, drug safety and pharmacovigilance, and R&D process improvement strategy. His client list consists of a majority of the prominent companies in the pharmaceutical, biotechnology, medical device, and generic drug spaces including the top ten pharma/medical device firms in the world.
For more than 15 years, Business & Decision has provided high-level Life Sciences consulting services across all business domains (R&D, Clinical/CRO, Manufacturing, Sales and Marketing) and in all industry sectors. Serving over 100 clients in the Life Sciences industry, the practice consists of more than 250 full-time Life Sciences specialists supported by more than 400 consultants with industry expertise.
SOURCE Business & Decision
Share this article